Published in Clin J Am Soc Nephrol on October 31, 2016
Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J (2017) 1.40
Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatr Nephrol (2017) 0.78
Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep (2017) 0.75
Eculizumab cessation in atypical hemolytic uremic syndrome. Blood (2017) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
New equations to estimate GFR in children with CKD. J Am Soc Nephrol (2009) 11.48
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis (2014) 3.55
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med (2006) 2.07
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int (2015) 1.85
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int (2016) 1.58
Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood (2015) 1.58
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int (2009) 1.55
Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods (2011) 1.46
An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2015) 1.42
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood (2014) 1.42
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome. Am J Kidney Dis (2015) 1.13
Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis (2013) 1.11
Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 1.08
Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis (2015) 0.96
Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet (2015) 0.95
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood (2015) 0.90
A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM (2015) 0.89
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. Am J Kidney Dis (2016) 0.88
Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. J Am Soc Nephrol (2015) 0.82
Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood (2016) 0.80
Defining the genetics of thrombotic microangiopathies. Transfus Apher Sci (2016) 0.78
Hemolytic Uremic Syndrome in Pregnancy and Post-Partum. Clin J Am Soc Nephrol (2017) 0.75